<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Amiya, E.</style></author><author><style face="normal" font="default" size="100%">Watanabe, M.</style></author><author><style face="normal" font="default" size="100%">Komuro, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Relationship between Vascular Function and the Autonomic Nervous System</style></title><secondary-title><style face="normal" font="default" size="100%">Ann Vasc Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Annals of vascular diseases</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ann Vasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of vascular diseases</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Ann Vasc Dis</style></full-title><abbr-1><style face="normal" font="default" size="100%">Annals of vascular diseases</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">109-19</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">autonomic nervous system</style></keyword><keyword><style face="normal" font="default" size="100%">endothelial cells</style></keyword><keyword><style face="normal" font="default" size="100%">endothelial function</style></keyword><keyword><style face="normal" font="default" size="100%">vascular function</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1881-641X (Print)&#xD;1881-641x</style></isbn><accession-num><style face="normal" font="default" size="100%">24995054</style></accession-num><abstract><style face="normal" font="default" size="100%">Endothelial dysfunction and autonomic nervous system dysfunction are both risk factors for atherosclerosis. There is evidence demonstrating that there is a close interrelationship between these two systems. In hypertension, endothelial dysfunction affects the pathologic process through autonomic nervous pathways, and the pathophysiological process of autonomic neuropathy in diabetes mellitus is closely related with vascular function. However, detailed mechanisms of this interrelationship have not been clearly explained. In this review, we summarize findings concerning the interrelationship between vascular function and the autonomic nervous system from both experimental and clinical studies. The clarification of this interrelationship may provide more comprehensive risk stratification and a new effective therapeutic strategy against atherosclerosis.</style></abstract><notes><style face="normal" font="default" size="100%">Amiya, Eisuke&#xD;Watanabe, Masafumi&#xD;Komuro, Issei&#xD;Journal Article&#xD;Review&#xD;Japan&#xD;Ann Vasc Dis. 2014;7(2):109-19. doi: 10.3400/avd.ra.14-00048. Epub 2014 May 16.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">Pmc4072858</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3400/avd.ra.14-00048</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Annalisa, N.</style></author><author><style face="normal" font="default" size="100%">Alessio, T.</style></author><author><style face="normal" font="default" size="100%">Claudette, T. D.</style></author><author><style face="normal" font="default" size="100%">Erald, V.</style></author><author><style face="normal" font="default" size="100%">Antonino, D. L.</style></author><author><style face="normal" font="default" size="100%">Nicola, D. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Hypertension and Nephrology, Department of System Medicine, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.&#xD;Departement of Diagnostic and Molecular Imaging, Interventional Radiology and Radiation Therapy, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.&#xD;Department of Biomedicine and Prevention, Division of Clinical Nutrition and Nutrigenomic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gut Microbioma Population: An Indicator Really Sensible to Any Change in Age, Diet, Metabolic Syndrome, and Life-Style</style></title><secondary-title><style face="normal" font="default" size="100%">Mediators Inflamm</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Mediators of inflammation</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mediators Inflamm</style></full-title><abbr-1><style face="normal" font="default" size="100%">Mediators of inflammation</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Mediators Inflamm</style></full-title><abbr-1><style face="normal" font="default" size="100%">Mediators of inflammation</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">901308</style></pages><volume><style face="normal" font="default" size="100%">2014</style></volume><edition><style face="normal" font="default" size="100%">2014/07/08</style></edition><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">0962-9351</style></isbn><accession-num><style face="normal" font="default" size="100%">24999296</style></accession-num><abstract><style face="normal" font="default" size="100%">Obesity has become a pandemic threat in the latest 30 years. The trend of the prevalence of overweight and obesity has got an overall increase in every part of the world, regardless of ethnicity, life-style and social ties. High food intake, genetic, and sedentary have been related to obesity; it has been also hypothesized that gut microbiota could have an impact on the complex mechanism underlying the weight gain. This review aims to illustrate the actual literature about gut microbiota and its relation with obesity and to analyze the possible implications of factors such as diet and life-style onto the composition of gut microbiota, that can lead to overweight/obesity condition.</style></abstract><notes><style face="normal" font="default" size="100%">1466-1861&#xD;Annalisa, Noce&#xD;Alessio, Tarantino&#xD;Claudette, Tsague Djoutsop&#xD;Erald, Vasili&#xD;Antonino, De Lorenzo&#xD;Nicola, Di Daniele&#xD;Review&#xD;Mediators Inflamm. 2014;2014:901308. Epub 2014 Jun 4.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2014/901308</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chrysant, S. G.</style></author><author><style face="normal" font="default" size="100%">Chrysant, G. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cardiology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma; Department of Cardiology, INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma. Electronic address: schrysant@yahoo.com.&#xD;Department of Cardiology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma; Department of Cardiology, INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Future of Polypill Use for the Prevention of Cardiovascular Disease and Strokes</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Cardiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">The American journal of cardiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Cardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">The American journal of cardiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Am J Cardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">The American journal of cardiology</style></abbr-1></alt-periodical><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0002-9149</style></isbn><accession-num><style face="normal" font="default" size="100%">24996555</style></accession-num><abstract><style face="normal" font="default" size="100%">Cardiovascular disease (CVD) remains still the leading cause of death in the United States, and it is estimated to be the leading cause of death in the developing countries by 2020. In addition, the modifiable cardiovascular risk factors (CVRFs), hypertension, hypercholesterolemia, diabetes, and obesity, have increased significantly and by 2020 will account for 80% of all CVD deaths worldwide. Because the CVD and stroke risk increases significantly for subjects aged &gt;50 years, it has been proposed to treat these subjects with a polypill containing 4 to 5 drugs, which is known to reduce the CVRFs for all subjects aged &gt;/=55 years with an estimated reduction of CVD and stroke by 80%. However, this proposal is neither practical nor cost-effective, because it will involve a large number of subjects. Some investigators suggest to incorporate the coronary artery calcium score (CACS) with the Framingham Risk Score (FRS) to reduce the number of subjects who will benefit from the polypill. They have shown that patients with a CACS = 0 at age 50 years will derive no benefit from the polypill regardless of existing CVRFs, whereas those with a CACS of &gt;100 will derive the best benefit. This strategy will reduce the number of qualified subjects for treatment with the polypill by 60%. Greater benefits will be derived with the combination of CACS and FRS. Additionally, other issues will have to be considered before approval of a polypill, and these issues will be discussed in this concise review. In conclusion, a polypill treatment strategy may be effective in the prevention of CVD and stroke, but, to be cost-effective, it may be reasonable to target patients with a high CACS and FRS.</style></abstract><notes><style face="normal" font="default" size="100%">1879-1913&#xD;Chrysant, Steven G&#xD;Chrysant, George S&#xD;Review&#xD;Am J Cardiol. 2014 Jun 6. pii: S0002-9149(14)01242-9. doi: 10.1016/j.amjcard.2014.05.049.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.amjcard.2014.05.049</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">4</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Estes, E. H.</style></author><author><style face="normal" font="default" size="100%">Kerivan, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Duke University Medical Center, Durham, NC. Electronic address: eestes@nc.rr.com.&#xD;Duke University Medical Center, Durham, NC.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An archaeologic dig: A rice-fruit diet reverses ECG changes in hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">J Electrocardiol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of electrocardiology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Electrocardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of electrocardiology</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Electrocardiol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of electrocardiology</style></abbr-1></alt-periodical><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">ECG changes with hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Reversal of ECG changes with hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Rice diet</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium restriction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 4</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0022-0736</style></isbn><accession-num><style face="normal" font="default" size="100%">24996514</style></accession-num><abstract><style face="normal" font="default" size="100%">In 1940, a young German refugee physician scientist at Duke University in Durham, North Carolina began to treat patients with accelerated or &quot;malignant&quot; hypertension with a radical diet consisting of only white rice and fruit, with strikingly favorable results. He reported rapid reduction in blood pressure, rapid improvement in renal failure, papilledema, congestive heart failure and other manifestations of this previously fatal illness. This treatment was based on his theory that the kidney had both an excretory and a metabolic function, and that removing most of the sodium and protein burden from this organ enabled it to regain its normal ability to perform its more important metabolic functions. It was also effective in &quot;ordinary&quot; hypertension, in the absence of the dramatic vasculopathy of the accelerated form. The results were so dramatic that many experienced physicians suspected him of falsifying data. Among these results was the normalization of the ECG changes seen with hypertension. This paper reviews his published experience with this radical therapy, its controversial rise to fame, and its decline in popularity with the advent of effective antihypertensive drugs. It features the ECG changes seen in this then fatal disease, and the reversal of these changes by the rice diet. This treatment, though very difficult for the patient, produced effects which make it equal or superior to current multi-drug treatment of hypertension. A poorly known but important observation was that patients who were able to follow the regime, and who were slowly guided through a gradual modification of the diet over many months, were able to transition into a very tolerable low fat, largely vegetarian diet, while leading a normal, active life, without medications, indicating that the disease state had been permanently modified.</style></abstract><notes><style face="normal" font="default" size="100%">1532-8430&#xD;Estes, E Harvey&#xD;Kerivan, Lauren&#xD;Review&#xD;J Electrocardiol. 2014 Jun 4. pii: S0022-0736(14)00165-4. doi: 10.1016/j.jelectrocard.2014.05.008.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jelectrocard.2014.05.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">King, C.</style></author><author><style face="normal" font="default" size="100%">May, C. W.</style></author><author><style face="normal" font="default" size="100%">Williams, J.</style></author><author><style face="normal" font="default" size="100%">Shlobin, O. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Critical Care Service, Inova Fairfax Hospital, 618 South Royal Street, Alexandria, VA 22314, USA. Electronic address: Csking123@hotmail.com.&#xD;Advanced Heart Failure and Cardiac Transplant Program, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.&#xD;Medical Critical Care Service, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.&#xD;Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA 22042, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of Right Heart Failure in the Critically Ill</style></title><secondary-title><style face="normal" font="default" size="100%">Crit Care Clin</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Critical care clinics</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Crit Care Clin</style></full-title><abbr-1><style face="normal" font="default" size="100%">Critical care clinics</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Crit Care Clin</style></full-title><abbr-1><style face="normal" font="default" size="100%">Critical care clinics</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">475-498</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acute respiratory distress syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Pulmonary hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">Right ventricular dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">Right ventricular failure</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0749-0704</style></isbn><accession-num><style face="normal" font="default" size="100%">24996606</style></accession-num><abstract><style face="normal" font="default" size="100%">Right ventricular failure complicates several commonly encountered conditions in the intensive care unit. Right ventricular dilation and paradoxic movement of the interventricular septum on echocardiography establishes the diagnosis. Right heart catheterization is useful in establishing the specific cause and aids clinicians in management. Principles of treatment focus on reversal of the underlying cause, optimization of right ventricular preload and contractility, and reduction of right ventricular afterload. Mechanical support with right ventricular assist device or veno-arterial extracorporeal membrane oxygenation can be used in select patients who fail to improve with optimal medical therapy.</style></abstract><notes><style face="normal" font="default" size="100%">1557-8232&#xD;King, Christopher&#xD;May, Christopher W&#xD;Williams, Jeffrey&#xD;Shlobin, Oksana A&#xD;Review&#xD;Crit Care Clin. 2014 Jul;30(3):475-498. doi: 10.1016/j.ccc.2014.03.003.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ccc.2014.03.003</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martinez-Varea, A.</style></author><author><style face="normal" font="default" size="100%">Pellicer, B.</style></author><author><style face="normal" font="default" size="100%">Perales-Marin, A.</style></author><author><style face="normal" font="default" size="100%">Pellicer, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynecology, Hospital Universitario y Politecnico La Fe, Avenida Bulevar Sur s/n, Valencia 46026, Spain.&#xD;Department of Obstetrics and Gynecology, Hospital General Universitario, Avenida Tres Cruces 2, Valencia 46014, Spain.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relationship between Maternal Immunological Response during Pregnancy and Onset of Preeclampsia</style></title><secondary-title><style face="normal" font="default" size="100%">J Immunol Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of immunology research</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Immunol Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of immunology research</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">J Immunol Res</style></full-title><abbr-1><style face="normal" font="default" size="100%">Journal of immunology research</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">210241</style></pages><volume><style face="normal" font="default" size="100%">2014</style></volume><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">2314-7156</style></isbn><accession-num><style face="normal" font="default" size="100%">24987708</style></accession-num><abstract><style face="normal" font="default" size="100%">Maternofetal immune tolerance is essential to maintain pregnancy. The maternal immunological tolerance to the semiallogeneic fetus becomes greater in egg donation pregnancies with unrelated donors as the complete fetal genome is allogeneic to the mother. Instead of being rejected, the allogeneic fetus is tolerated by the pregnant woman in egg donation pregnancies. It has been reported that maternal morbidity during egg donation pregnancies is higher as compared with spontaneous or in vitro fertilization pregnancies. Particularly, egg donation pregnancies are associated with a higher incidence of pregnancy-induced hypertension and placental pathology. Preeclampsia, a pregnancy-specific disease characterized by the development of both hypertension and proteinuria, remains the leading cause of maternal and perinatal mortality and morbidity. The aim of this review is to characterize and relate the maternofetal immunological tolerance phenomenon during pregnancies with a semiallogenic fetus, which are the spontaneously conceived pregnancies and in vitro fertilization pregnancies, and those with an allogeneic fetus or egg donation pregnancies. Maternofetal immune tolerance in uncomplicated pregnancies and pathological pregnancies, such as those with preeclampsia, has also been assessed. Moreover, whether an inadequate maternal immunological response to the allogenic fetus could lead to a higher prevalence of preeclampsia in egg donation pregnancies has been addressed.</style></abstract><notes><style face="normal" font="default" size="100%">2314-7156&#xD;Martinez-Varea, Alicia&#xD;Pellicer, Begona&#xD;Perales-Marin, Alfredo&#xD;Pellicer, Antonio&#xD;Review&#xD;J Immunol Res. 2014;2014:210241. Epub 2014 Jun 2.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">Pmc4060291</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2014/210241</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Neumiller, J. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs Context</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Drugs in context</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs Context</style></full-title><abbr-1><style face="normal" font="default" size="100%">Drugs in context</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Drugs Context</style></full-title><abbr-1><style face="normal" font="default" size="100%">Drugs in context</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">212262</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">blood glucose</style></keyword><keyword><style face="normal" font="default" size="100%">combination drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">empagliflozin</style></keyword><keyword><style face="normal" font="default" size="100%">hemoglobin A1c protein</style></keyword><keyword><style face="normal" font="default" size="100%">hypertension</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">sodium-glucose co-transporter 2 (SGLT2) inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">type 2 diabetes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><isbn><style face="normal" font="default" size="100%">1745-1981 (Print)&#xD;1740-4398</style></isbn><accession-num><style face="normal" font="default" size="100%">24991224</style></accession-num><abstract><style face="normal" font="default" size="100%">Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin-independent mechanism for improving blood glucose levels, since they promote urinary glucose excretion (UGE) by inhibiting glucose reabsorption in the kidney. In addition to glucose control, SGLT2 inhibitors are associated with weight loss and blood pressure reductions, and do not increase the risk of hypoglycemia. Empagliflozin is a selective inhibitor of SGLT2, providing dose-dependent UGE increases in healthy volunteers, with up to 90 g of glucose excreted per day. It can be administered orally, and studies of people with renal or hepatic impairment indicated empagliflozin needed no dose adjustment based on pharmacokinetics. In Phase II trials in patients with type 2 diabetes, empagliflozin provided improvements in glycosylated hemoglobin (HbA1c) and other measures of glycemic control when given as monotherapy or add-on to metformin, as well as reductions in weight and systolic blood pressure. As add-on to basal insulin, empagliflozin not only improved HbA1c levels but also reduced insulin doses. Across studies, empagliflozin was generally well tolerated with a similar rate of hypoglycemia to placebo; however, patients had a slightly increased frequency of genital infections, but not urinary tract infections, versus placebo. Phase III studies have also reported a good safety profile along with significant improvements in HbA1c, weight and blood pressure, with no increased risk of hypoglycemia versus placebo. Based on available data, it appears that empagliflozin may be a useful option in a range of patients; however, clinical decisions will be better informed by the results of ongoing studies, in particular, a large cardiovascular outcome study (EMPA-REG OUTCOME).</style></abstract><notes><style face="normal" font="default" size="100%">Neumiller, Joshua J&#xD;Journal Article&#xD;Review&#xD;England&#xD;Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">Pmc4079288</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.7573/dic.212262</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palagini, L.</style></author><author><style face="normal" font="default" size="100%">Gemignani, A.</style></author><author><style face="normal" font="default" size="100%">Banti, S.</style></author><author><style face="normal" font="default" size="100%">Manconi, M.</style></author><author><style face="normal" font="default" size="100%">Mauri, M.</style></author><author><style face="normal" font="default" size="100%">Riemann, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Experimental Medicine, Psychiatric Unit, University of Pisa, School of Medicine, Pisa, Italy. Electronic address: l.palagini@ao-pisa.toscana.it.&#xD;Department of Surgery, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.&#xD;Department of Clinical Experimental Medicine, Psychiatric Unit, University of Pisa, School of Medicine, Pisa, Italy.&#xD;Sleep Center, Neurocenter of Southern Switzerland, Civic Hospital of Lugano, Switzerland.&#xD;Department of Psychiatry &amp; Psychotherapy, University of Freiburg Medical Center, Freiburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chronic sleep loss during pregnancy as a determinant of stress: impact on pregnancy outcome</style></title><secondary-title><style face="normal" font="default" size="100%">Sleep Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sleep medicine</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sleep Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Sleep medicine</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Sleep Med</style></full-title><abbr-1><style face="normal" font="default" size="100%">Sleep medicine</style></abbr-1></alt-periodical><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Allostatic load</style></keyword><keyword><style face="normal" font="default" size="100%">Insomnia</style></keyword><keyword><style face="normal" font="default" size="100%">Poor sleep quality</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep loss</style></keyword><keyword><style face="normal" font="default" size="100%">Stress</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 27</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1389-9457</style></isbn><accession-num><style face="normal" font="default" size="100%">24994566</style></accession-num><abstract><style face="normal" font="default" size="100%">Short sleep duration, poor sleep quality, and insomnia frequently characterize sleep in pregnancy during all three trimesters. We aimed: (i) to review the clinical evidence of the association between conditions of sleep loss during pregnancy and adverse pregnancy outcomes; and (ii) to discuss the potential pathophysiological mechanisms that may be involved. A systematic search of cross-sectional, longitudinal studies using Medline, Embase, and PsychINFO, and MeSH headings and key words for conditions of sleep loss such as &apos;insomnia&apos;, &apos;poor sleep quality&apos;, &apos;short sleep duration&apos;, and &apos;pregnancy outcome&apos; was made for papers published between January 1, 1960 and July 2013. Twenty studies met inclusion criteria for sleep loss and pregnancy outcome: seven studies on prenatal depression, three on gestational diabetes, three on hypertension, pre-eclampsia/eclampsia, six on length of labor/type of delivery, eight on preterm birth, and three on birth grow/birth weight. Two main results emerged: (i) conditions of chronic sleep loss are related to adverse pregnancy outcomes; and (ii) chronic sleep loss yields a stress-related hypothalamic-pituitary-adrenal axis and abnormal immune/inflammatory, reaction, which, in turn, influences pregnancy outcome negatively. Chronic sleep loss frequently characterizes sleep throughout the course of pregnancy and may contribute to adverse pregnancy outcomes. Common pathophysiological mechanisms emerged as being related to stress system activation. We propose that in accordance to the allostatic load hypothesis, chronic sleep loss during pregnancy may also be regarded as both a result of stress and a physiological stressor per se, leading to stress &apos;overload&apos;. It may account for adverse pregnancy outcomes and somatic and mental disorders in pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">1878-5506&#xD;Palagini, Laura&#xD;Gemignani, Angelo&#xD;Banti, Susanna&#xD;Manconi, Mauro&#xD;Mauri, Mauro&#xD;Riemann, Dieter&#xD;Review&#xD;Sleep Med. 2014 May 27. pii: S1389-9457(14)00171-3. doi: 10.1016/j.sleep.2014.02.013.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.sleep.2014.02.013</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">7</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rubin, B. K.</style></author><author><style face="normal" font="default" size="100%">Williams, R. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Virginia Commonwealth University School of Medicine, Children&apos;s Hospital of Richmond at VCU, 1001 East Marshall St., PO Box 980646, Richmond, VA 23298, USA. Electronic address: brubin@vcu.edu.&#xD;Division of Pediatric Pulmonary, Department of Pediatrics, Virginia Commonwealth University School of Medicine, Children&apos;s Hospital of Richmond at VCU, PO Box 980315, Richmond, VA 23298, USA. Electronic address: rwwilliams@vcu.edu.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emerging aerosol drug delivery strategies: From bench to clinic</style></title><secondary-title><style face="normal" font="default" size="100%">Adv Drug Deliv Rev</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Advanced drug delivery reviews</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Adv Drug Deliv Rev</style></full-title><abbr-1><style face="normal" font="default" size="100%">Advanced drug delivery reviews</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">Adv Drug Deliv Rev</style></full-title><abbr-1><style face="normal" font="default" size="100%">Advanced drug delivery reviews</style></abbr-1></alt-periodical><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aerosol therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Engineered particle</style></keyword><keyword><style face="normal" font="default" size="100%">Nebulizer</style></keyword><keyword><style face="normal" font="default" size="100%">Pressurized metered dose inhaler</style></keyword><keyword><style face="normal" font="default" size="100%">Vibrating mesh nebulizer</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0169-409x</style></isbn><accession-num><style face="normal" font="default" size="100%">24993613</style></accession-num><abstract><style face="normal" font="default" size="100%">Patients with tracheostomies, those requiring mechanical ventilation, and those too small or compromised for conventional devices, are realizing the benefits of increasingly sophisticated aerosol delivery systems. New medicines and novel aerosol formulations, have enhanced our ability to treat lung disease, and are opening the doors for therapy to treat diseases like diabetes, pulmonary hypertension, and cancer. Progress in the aerosol delivery of drugs has been spurred by the significant benefits, including ease of use, patient comfort, greater selectivity of effect, and the potential to decrease side effects.</style></abstract><notes><style face="normal" font="default" size="100%">1872-8294&#xD;Rubin, Bruce K&#xD;Williams, Ronald W&#xD;Review&#xD;Adv Drug Deliv Rev. 2014 Jun 30. pii: S0169-409X(14)00140-9. doi: 10.1016/j.addr.2014.06.008.</style></notes><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.addr.2014.06.008</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">Eng</style></language></record><record><database name="TestLibrary.enl" path="C:\Users\TestC\Documents\TestLibrary.enl">TestLibrary.enl</database><source-app name="EndNote" version="17.1">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="fzp5ar20q090wae90dqvzs21s2090a22vsxv">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toshner, M.</style></author><author><style face="normal" font="default" size="100%">Pepke-Zaba, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Papworth Hospital Papworth Everard, Cambridge, CB23 3RE UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment</style></title><secondary-title><style face="normal" font="default" size="100%">F1000Prime Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">F1000prime reports</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">F1000Prime Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">F1000prime reports</style></abbr-1></periodical><alt-periodical><full-title><style face="normal" font="default" size="100%">F1000Prime Rep</style></full-title><abbr-1><style face="normal" font="default" size="100%">F1000prime reports</style></abbr-1></alt-periodical><pages><style face="normal" font="default" size="100%">38</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><edition><style face="normal" font="default" size="100%">2014/07/06</style></edition><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><accession-num><style face="normal" font="default" size="100%">24991415</style></accession-num><abstract><style face="normal" font="default" size="100%">The modern treatment era in chronic thromboembolic disease has seen significant advances in both surgical and medical treatment. One such treatment, the pulmonary endarterectomy (where established chronic organized thrombus is removed), has dramatically affected morbidity and mortality. These advances have outstripped basic research into the causes and pathophysiology of disease, which remain largely poorly understood. In this review, we will set out to explain some of the historical reasons for this, including the difficulties inherent in human studies and the lack of good animal models. We will review some of the recent advances in pathophysiology from registries and translational research, and we will summarize the treatment options, with some discussion of very recently published work, including medical and surgical treatments, both traditional and more experimental work in non-invasive techniques.</style></abstract><notes><style face="normal" font="default" size="100%">2051-7599&#xD;Toshner, Mark&#xD;Pepke-Zaba, Joanna&#xD;Journal Article&#xD;Review&#xD;England&#xD;F1000Prime Rep. 2014 Jun 2;6:38. doi: 10.12703/P6-38. eCollection 2014.</style></notes><urls></urls><custom2><style face="normal" font="default" size="100%">Pmc4047953</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.12703/p6-38</style></electronic-resource-num><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>
